SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001829126-23-002504
Filing Date
2023-03-31
Accepted
2023-03-31 16:30:49
Documents
66
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K titanpharma_10k.htm   iXBRL 10-K 1223011
2 EXHIBIT 23.1 titanpharma_ex23-1.htm EX-23.1 4145
3 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 16260
4 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 8212
  Complete submission text file 0001829126-23-002504.txt   5143681

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ttnp-20221231.xsd EX-101.SCH 38974
6 XBRL CALCULATION FILE ttnp-20221231_cal.xml EX-101.CAL 51025
7 XBRL DEFINITION FILE ttnp-20221231_def.xml EX-101.DEF 137802
8 XBRL LABEL FILE ttnp-20221231_lab.xml EX-101.LAB 319025
9 XBRL PRESENTATION FILE ttnp-20221231_pre.xml EX-101.PRE 251937
60 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10k_htm.xml XML 697585
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-13341 | Film No.: 23788295
SIC: 2836 Biological Products, (No Diagnostic Substances)